Overview

A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

Status:
Completed

Trial end date:
2018-11-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Capecitabine
Gemcitabine